Evaluative framework for phase II studies in patients with heart failure and preserved ejection fraction

JACC Heart Fail. 2013 Apr;1(2):123-6. doi: 10.1016/j.jchf.2013.01.001. Epub 2013 Apr 1.

Authors

Mihai Gheorghiade¹, Muthiah Vaduganathan², Sanjiv J Shah³

Affiliations

¹ Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: m-gheorghiade@northwestern.edu.
² Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
³ Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

PMID: 24621837
DOI: 10.1016/j.jchf.2013.01.001

No abstract available

Keywords: diastolic dysfunction; heart failure with preserved ejection fraction; late sodium current inhibition.

Publication types

Editorial
Comment

MeSH terms

Acetanilides / therapeutic use*
Female
Heart Failure, Diastolic / drug therapy*
Humans
Male
Piperazines / therapeutic use*
Ranolazine
Sodium Channel Blockers / therapeutic use*

Substances

Acetanilides
Piperazines
Sodium Channel Blockers
Ranolazine